PCN38 - NIVOLUMAB IS PREDICTED TO HAVE IMPROVED CLINICAL OUTCOMES OVER BEST SUPPORTIVE CARE IN A WESTERN POPULATION OF PRE-TREATED GASTRIC CANCER PATIENTS; AN INDIRECT TREATMENT COMPARISON ANALYSIS
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.120
https://www.valueinhealthjournal.com/article/S1098-3015(18)33420-X/fulltext
Section Title :
Section Order :
639
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33420-X&doi=10.1016/j.jval.2018.09.120